evidence table

Curcumin Knee Pain Randomized Trial Evidence Table

Structured evidence table for Curcumin Knee Pain Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Curcumin Knee Pain Randomized TrialResults Compared to the placebo, VAS-101 was associated with greater improvements in the KOOS pain score (primary outcome measure) (β: 5.12; 95% CI: 0.47, 9.77; d = 0.62, p = 0.041), and mean daily pain ratings (F 3, 225 = 4.42; d = 0.55, p = 0.005).2Lopresti AL (2026)The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
Curcumin Knee Pain Randomized TrialIn the VAS-101 group, 39.3% of participants reported feeling either much or very much improved, compared with 13.3% in the placebo group ( p = 0.019).2Lopresti AL (2026)The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
Curcumin Knee Pain Randomized TrialConclusions Conservative dosing of a topically applied curcumin-containing gel (VAS-101), administered every two days for 28 days, is associated with moderate reductions in knee pain in adults with knee osteoarthritis.2Lopresti AL (2026)The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
Curcumin Knee Pain Randomized TrialBackground The oral delivery of curcumin has been shown in several studies to have beneficial pain-relieving effects for the treatment of knee osteoarthritis.2Lopresti AL (2026)The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
Curcumin Knee Pain Randomized Trial1 2 Arthritis constitutes a major global health burden and remains one of the leading causes of chronic pain, disability, and reduced quality of life worldwide.3Toumi Hechmi (2026)Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
Curcumin Knee Pain Randomized TrialOA is primarily a degenerative disease associated with aging and mechanical stress, whereas RA is an autoimmune disorder characterized by systemic inflammation and synovial hyperplasia [,].3Toumi Hechmi (2026)Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
Curcumin Knee Pain Randomized TrialAlthough these therapies can alleviate symptoms and, in some cases, slow disease progression, their long-term use is often associated with significant adverse effects, including gastrointestinal, cardiovascular, renal, and immunological complications [].3Toumi Hechmi (2026)Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
Curcumin Knee Pain Randomized TrialThe two most prevalent forms, osteoarthritis (OA) and rheumatoid arthritis (RA), differ in etiology but share common pathological features, including joint inflammation, cartilage degradation, and progressive functional impairment.3Toumi Hechmi (2026)Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
topicCurcumin Knee Pain Randomized Trial
claimResults Compared to the placebo, VAS-101 was associated with greater improvements in the KOOS pain score (primary outcome measure) (β: 5.12; 95% CI: 0.47, 9.77; d = 0.62, p = 0.041), and mean daily pain ratings (F 3, 225 = 4.42; d = 0.55, p = 0.005).
evidence level2
citationLopresti AL (2026)
sourceThe effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
topicCurcumin Knee Pain Randomized Trial
claimIn the VAS-101 group, 39.3% of participants reported feeling either much or very much improved, compared with 13.3% in the placebo group ( p = 0.019).
evidence level2
citationLopresti AL (2026)
sourceThe effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
topicCurcumin Knee Pain Randomized Trial
claimConclusions Conservative dosing of a topically applied curcumin-containing gel (VAS-101), administered every two days for 28 days, is associated with moderate reductions in knee pain in adults with knee osteoarthritis.
evidence level2
citationLopresti AL (2026)
sourceThe effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
topicCurcumin Knee Pain Randomized Trial
claimBackground The oral delivery of curcumin has been shown in several studies to have beneficial pain-relieving effects for the treatment of knee osteoarthritis.
evidence level2
citationLopresti AL (2026)
sourceThe effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
topicCurcumin Knee Pain Randomized Trial
claim1 2 Arthritis constitutes a major global health burden and remains one of the leading causes of chronic pain, disability, and reduced quality of life worldwide.
evidence level3
citationToumi Hechmi (2026)
sourceCurcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
topicCurcumin Knee Pain Randomized Trial
claimOA is primarily a degenerative disease associated with aging and mechanical stress, whereas RA is an autoimmune disorder characterized by systemic inflammation and synovial hyperplasia [,].
evidence level3
citationToumi Hechmi (2026)
sourceCurcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
topicCurcumin Knee Pain Randomized Trial
claimAlthough these therapies can alleviate symptoms and, in some cases, slow disease progression, their long-term use is often associated with significant adverse effects, including gastrointestinal, cardiovascular, renal, and immunological complications [].
evidence level3
citationToumi Hechmi (2026)
sourceCurcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications
topicCurcumin Knee Pain Randomized Trial
claimThe two most prevalent forms, osteoarthritis (OA) and rheumatoid arthritis (RA), differ in etiology but share common pathological features, including joint inflammation, cartilage degradation, and progressive functional impairment.
evidence level3
citationToumi Hechmi (2026)
sourceCurcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications

Learn next

Related evidence and supplement guides

SupplementCurcumin (Turmeric)Turmeric's active compound with potent anti-inflammatory properties — bioavailability is the cri...GuideCurcumin Knee Pain Randomized Trial: What the Evidence SaysCurcumin Knee Pain Randomized Trial has 2 source documents in the current Migaku evidence databa...GuideCurcumin Sleep Quality Randomized Trial: What the Evidence SaysCurcumin Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence da...GuideCurcumin Joint Stiffness Randomized Trial: What the Evidence SaysCurcumin Joint Stiffness Randomized Trial has 2 source documents in the current Migaku evidence...GuideGlucosamine Knee Discomfort Randomized Trial: What the Evidence SaysGlucosamine Knee Discomfort Randomized Trial has 2 source documents in the current Migaku eviden...CompareCurcumin BCM95 vs Curcumin Standard ExtractBCM95 is a patented curcumin with superior bioavailability compared to standard curcumin extract...AnswerDoes Curcumin Knee Pain Randomized Trial work?Curcumin Knee Pain Randomized Trial has evidence relevant to strength of evidence and what the s...AnswerIs Curcumin Knee Pain Randomized Trial safe?Curcumin Knee Pain Randomized Trial has evidence relevant to safety, limits, and clinician-discu...

Source documents

  1. The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study.
  2. Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications